The INSIGHT study is a phase Ib/II trial that investigated the combination of tepotinib and gefitinib in patients with EGFR-mutant, T790M negative NSCLC with acquired resistance to EGFR TKI therapy compared to chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.